Outlook Therapeutics, Inc.
OTLK
$0.39
$0.0410.88%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -45.68% | -14.60% | 43.93% | 62.26% | 62.26% |
| Gross Profit | 46.30% | 19.60% | -36.65% | -62.26% | -62.26% |
| SG&A Expenses | 1.41% | 33.39% | 47.47% | 49.91% | 35.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.73% | -4.50% | 20.96% | 27.69% | 73.75% |
| Operating Income | 28.98% | 6.47% | -18.50% | -27.69% | -73.75% |
| Income Before Tax | -123.07% | 15.11% | 53.81% | 113.27% | 9.10% |
| Income Tax Expenses | -55,521.43% | -55,521.43% | 0.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | -119.74% | 17.17% | 53.81% | 113.27% | 9.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -119.74% | 17.17% | 53.81% | 113.27% | 9.10% |
| EBIT | 28.98% | 6.47% | -18.50% | -27.69% | -73.75% |
| EBITDA | 29.02% | 6.49% | -18.50% | -27.66% | -73.74% |
| EPS Basic | 47.25% | 76.01% | 86.30% | 111.92% | -28.94% |
| Normalized Basic EPS | -94.53% | 47.08% | 76.63% | 115.90% | 63.62% |
| EPS Diluted | 65.76% | 83.00% | 89.82% | 87.55% | -99.04% |
| Normalized Diluted EPS | -75.81% | 49.55% | 77.41% | 113.91% | 59.75% |
| Average Basic Shares Outstanding | 105.05% | 87.58% | 82.31% | 92.10% | 65.32% |
| Average Diluted Shares Outstanding | 99.79% | 82.07% | 76.07% | 96.33% | 69.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |